Clinical trial
Lomustine and Intermediate Dose Cytarabine in Older Patients With AML
NCT00480064 · French Innovative Leukemia Organisation, Other · Completed
Key facts
| NCT number | NCT00480064 |
|---|---|
| Title | Lomustine and Intermediate Dose Cytarabine in Older Patients With AML |
| Official title | Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction Chemotherapy and Adding Intermediate Dose Cytarabine to Consolidation in Older Patients With Acute Myeloid Leukaemia |
| Lead sponsor | French Innovative Leukemia Organisation, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Lomustine, intermediate dose cytarabine |
| Enrollment | 360 |
| Start date | Jul 1, 1995 |
| Completion | May 1, 2007 |
| First posted | May 30, 2007 |
| Last update posted | May 30, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: